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Abstract In chronic myeloid leukemia (CML), the presence
of a specific chromosomemarker (Ph-chromosome) as well as
of the corresponding molecular marker (BCR-ABL fusion
transcripts) provides suitable and precise tools to monitor the
burden of the disease present at diagnosis and that of the
residual disease present at specific time points during treat-
ment. A huge number of studies have clearly demonstrated
that in CML cytogenetic and molecular responses are strictly
correlated to the final outcome of the patients and the correct
use of standardized methods to assess the achievement of
specific degrees of disease reduction at specific time points
during treatment has become an essential part of proper clin-
ical management of CML. The target to be achieved and the
corresponding Boptimal response^ definition are however
evolving, and at least for some patients, they may be repre-
sented not only by best possible overall survival (OS) but also
by the possibility to discontinue the tyrosine-kinase inhibitor
(TKI) treatment and therefore to live in a treatment-free remis-
sion (TFR) status. Therefore, at least for some patients, deep
degrees of molecular response, as MR4 and MR4.5, whose
precise definition has been recently introduced and that are
prerequisites to try to discontinuation, are becoming the target
to be achieved even in common clinical practice. As a fast
initial decline of the disease burden after therapy start may
be highly predictive for the final outcome of patients not only
in terms of progression-free survival (PFS) and of PS but also
in terms of possibility of achieving deep molecular responses,
a more intense and punctual monitoring of the response of
CML patients during the first 6 months of TKI therapy is
now recommended by the more recent versions of the Euro-
pean Leukemia Net (ELN) and National Comprehensive Can-
cer Network (NCCN) guidelines, as this represents the major
driver to decide therapy.
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Introduction
The degree of leukemia load reduction during therapy is the
most important prognostic factor for chronic myeloid leuke-
mia (CML) patients [1, 2].
Various analyses have shown that patients who do not
achieve good cytogenetic or molecular responses have a
worse outcome, characterized by an increased risk of relapse,
of progression, and of death [3, 4]. Based on these principles, a
panel of CML experts on behalf of the European Leukemia
Net (ELN) aswell as members of the National Comprehensive
Cancer Network (NCCN) have previously established and
continuously revised treatment milestones to be achieved dur-
ing CML treatment with tyrosine-kinase inhibitors (TKIs)
[5••, 6••]. Indeed, criteria based on the degree of hematologic,
cytogenetic, and molecular response expected at defined time
points (considering that CML responses follow a sequential
order that begins with hematologic remission and continues
with cytogenetic and molecular response) have been derived
from data of different studies showing that patients who do not
present a certain degree of response at a given time show a
worse progression-free survival (PFS) and overall survival
(OS) than those who do it [7•, 8, 9]. Optimal response is
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intended when the response obtained is the one associated
with an optimal OS, and there is therefore no need, in presence
of a good tolerance, to change the TKI therapy [5••]. Failure is
intended when the residual probabilities of achieving an opti-
mal response are indeed very scarce and therefore, when and if
possible, while warning or suboptimal response correspond to
intermediate situations between optimal response and failure,
in which the reduction of the Ph-positive clone is slower than
expected for an optimal response, but there are still substantial
possibilities for the patient to achieve the planned degree of
response later on [5••]. This obviously implies that an appro-
priate and timely follow-up with cytogenetic and standardized
molecular methods of adequate reliability is essential even in
usual clinical practice [10–12]. In particular, molecular mon-
itoring of BCR-ABL transcript levels by real-time quantitative
PCR (RQ PCR) is progressively becoming the most precise
way to monitor CML patients. With respect to conventional
cytogenetic analysis, RQ PCR cannot only allow to monitor
the first steps of reduction of the leukemic burden occurring
within the first months of TKI therapy, but it may also allow to
estimate the amount of the residual disease once complete
cytogenetic response (CCyR) is achieved, as the sensitivity
that can be reached with the present RQ PCR procedures in
a sample of good quality is in most cases between 1×10−4/
10−5 that corresponds to an amount between 2 and 3 logs
below the threshold of the achievement of CCyR [13]. As
we will see, the achievement of a very low number of leuke-
mic cells is associated with the possibility to try to discontinue
the therapy with a substantial probability to remain in remis-
sion without the need to restart the therapy [14–16].
Finally, it has been established that mutations in the BCR-
ABL kinase domain (KD) represent a frequent phenomenon
associated with resistance to TKIs [17]. The early detection
and characterization of these mutations may allow timely and
appropriate treatment intervention to overcome resistance.
Cytogenetic and Molecular Milestones
to Be Achieved in CMLTherapy
In the more recent version of both ELN and NCCN recom-
mendations, to match the Boptimal response^ definition, the
relevant BCR-ABL% to be reached are the following: (a) at
3 months 10 % BCR-ABL according to the established inter-
national scale (IS) that represents 1 log reduction with respect
to the median BCR-ABL amount present at diagnosis and that
roughly corresponds to the threshold of partial cytogenetic
response PCyR; (b) at 6 months 1 % BCR-ABLIS that repre-
sents 2-log reduction with respect to the median BCR-ABL
amount present at diagnosis and that roughly corresponds to
the threshold of complete cytogenetic response CCyR); and
(c) at 12 months 0.10 % BCR-ABLIS (major molecular re-
sponse (MMR)), later on to maintain MMR or to reach
0.01 % and to 0.0032 % BCR-ABL corresponding, respec-
tively, toMR4 (4-log reduction) andMR4.5 (4.5-log reduction)
[5••, 6••] (Fig. 1).
From the practical point of view, even in our days probably
the attainment of CCyR or 1 % BCR-ABL can still be con-
sidered the most significant response to target, as this goal has
been demonstrated to be associated to the highest probability
of long-term survival for CML patients who better benefit
from the TKI therapy are those who achieve and maintain
CCyR for at least 2 years, as in these cases the OS is similar
to that of a control population without leukemia [7•, 8, 9, 18].
However, whereas in previous editions of the ELN recom-
mendations, this goal was expected at 12 months from start
of therapy, in the last versions of both guidelines, CCyR or
1%BCR-ABLIS is expected already after 6 months of therapy
only. This was based on the observation that the landmark
analysis at 6 months of the patients in CCyR or not are equally
well predictive for PFS and OS than that at 12months with the
advantage that of course the analysis is at an early time point
and it is able to predict for more events [7•].
Several sets of data did not appear to support the notion that
deeper responses, as the achievement of level of BCR-ABLIS
≤0.1 % (MMR) may indeed improve OS relative to achieve
CCyRwithoutMMR [7•, 8]. More recently, however, a 4-year
landmark analysis performed within the context of the Ger-
man CML study IV suggests that the patients who after 4 years
were able to achieve a stable MR4.5 molecular response, at
8 years show a statistically significant better survival with
respect to those patients who have simply achieved CCyR
but not MMR [9]. If these results will be confirmed, MR4.5
will represent a new molecular predictor of long-term
outcome.
In any case, it is has been clearly established by several
clinical studies that a stable deep molecular response (at least
MR4 or even better MR4.5) is requested to obtain a long-
lasting treatment-free remission (TFR) that is progressively
becoming the new treatment goal for many CML patients
[14, 15]. Thus, the achievement of MMR4 and of MR4.5 in
addition to CCyR and MMR are appealing targets to pursue,
as they predict for more durable and stable responses and can
also open the possibility to try to stop the therapy.
It is noteworthy that many studies, particularly in more
recent years, have indicated that early cytogenetic and early
molecular responses (EMR) within the first year of therapy
represent the strongest prognostic parameters [19•, 20–22].
This is not only in terms of OS, progression-free survival
(PFS), or event-free survival (EFS) but also in terms of possi-
bility of achieving deeper molecular responses and therefore
the possibility of discontinuing treatment without molecular
relapse (TFR). Based on these observations, the last editions
of the ELN and NCCN recommendations have been modified
with respect to the past, the time points at which the expected
response goals should be met to match the criteria for optimal
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response [5••, 6••]. Whereas previously only hematologic re-
mission and some degree of cytogenetic response were ex-
pected after 3 months of TKI therapy, partial cytogenetic re-
sponse (PCyR) after 6 months and CCyR after 1 year, in the
last editions of both ELN and NCCN recommendations, to be
considered Boptimal responders,^ the patients should at least
be in partial cytogenetic response (PCyR) and/or below the
roughly corresponding 10 %IS BCR-ABL threshold after
3 months of therapy, at least in CCyR and/or below the
1 %IS BCR-ABL level after 6 months of therapy and at least
in MMR after 1 year of therapy and thereafter show a contin-
uous decline of the BCR-ABL level until the achievement of
deeper responses like MR4 or MR4,5 [5••, 6••].
Indeed, many studies suggest that the most clinically rele-
vant target to be achieved during TKI therapy is represented
by a reduction of the BCR-ABL transcript level below 10 %IS
at 3 months, as this is associated with a high statistically sig-
nificant difference in terms of OS and PFS [19•, 20–22].
Parameters to Change the TKI Therapy
The reasons underlying the decision of changing TKI therapy
may be different. In addition to the cases of overt failure and
therefore at higher risk of progression and of death, in general
10–12 % of patients may show adverse events (AEs) and
become intolerant to treatment with a given TKI and should
bemoved to the treatment with another drug [23]. Considering
all together the reasons leading to discontinuation of a specific
TKI, several reports have shown that after 8 years from diag-
nosis, only approximately 55–60% of the patients who started
with imatinib are still on treatment with this drug [24]. Not a
substantial difference has been observed among patients who
started therapy with second-generation TKIs as first-line ther-
apy [25, 26]. Therefore, the present-day possibility to have at
disposition several TKIs with different characteristics and dif-
ferent toxicity profiles to be used as first-, second-, or third-
line therapy represents a great advantage with respect to the
past.
However, the most difficult decision to be taken is when to
change therapy in case of Bnonoptimal response.^ Based on
the parameter of a cutoff of 10 %IS BCR-ABL at 3 months, it
appears that approximately one third of CML patients do not
show an optimal response to imatinib therapy and they are
therefore facing a statistically significant higher risk of an
inferior outcome in terms of EFS, PFS, and also OS (approx-
imately 80 % at 5 years with respect to >95 % of those below
10%BCR-ABL at 3 months) [19•, 20–22]. This percentage is
much lower (approximately 10–15 %) among the patients
who started first-line therapy with the second-generation
TKIs, but the outcome of these patients is probably even
worse with respect to those who do not obtain the response
with imatinib [21, 22].
On this aspect, there are discordant indications in the last
version of the ELN with respect to what was recommended in
the last version of the NCCN guidelines [5••, 6••]. Whereas
the latter, for the cases who do not achieve a 10 %IS BCR-
ABL cutoff at 3 months, suggests to change TKI therapy, in
the ELN recommendations, a more delaying position is sug-
gested for those that are simply above 10 % but not yet overt
failures. From the practical point of view, the ELN recommen-
dations suggest simply to look more carefully at those cases
by increasing the frequency of the RQ PCR tests and to
change therapy only if at 6 months the percentage of BCR-
ABL is above 10 %, at this time considered failure [5••].
Actually, it is true that most of these patients (approximate-
ly 80 % of those first-line treated with imatinib) will only
show a delayed response and that, in case of an overt failure,
they will simply require a switch to treatment with a second-
generation TKI to achieve a good response in at least 40–50%
of the cases [27, 28]. However, it should also be considered
that approximately 15–20 % of them in a short time will prog-
ress to a more advanced phase of the disease and will die [19•,
20–22]. Most of these progressions occur in patients who at
Fig. 1 Monitoring of molecular
response in CML by RQ PCR.
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diagnosis were classified as high or intermediate Sokal’s risk
group and progressions are rare in the low Sokal’s risk group
in TKI-treated patients. This may be related to the observation
the percentage of the patients who do not show an optimal
response to imatinib may vary according to the initial clinical
and hematological features that determine their initial risk cat-
egory as established by the Sokal’s, Euro, and also by the
more recent EUTOS score [29–31]. In the IRIS study, patients
with low-, intermediate-, or high-risk Sokal’s score showed
significantly different response rates [32]. In the ENESTnd
study, a trial comparing imatinib versus nilotinib as first-line
treatment for CML, shows that the use of more potent TKIs as
those of second generation can indeed greatly increase the
percentage of the patients who at 3 months achieve a value
of BCR-ABL trascripts below the 10 %IS in the high and
intermediate Sokal’s risk groups: the percentage of the high-
risk group patients achieving a value of BCR-ABLIS <10 %
when treated with nilotinib (85 %) is almost double with re-
spect to what is observed in the group treated with imatinib
(43 %) [33]. This may explain the reduction of the progres-
sions within the first months after start of therapy observed in
the patients treated with second-generation TKIs with respect
to those treated with imatinib that is particularly evident in the
intermediate and high-risk Sokal’s groups, and this also rep-
resents the rationale of several clinical trials aiming to improve
the first-line treatment of CML patients in order to decrease
the number of the patients not achieving an optimal response
[34]. The therapeutic strategies so far tested include first-line
administration of the second-generation TKIs originally used
as second-line therapy or modified imatinib-based regimens,
as higher dosages of imatinib from the start or combinations of
imatinib with other drugs, namely interferon-alpha (IFN-α)
[34]. At present, only the use of the second-generation TKIs
nilotinib at the dosage of 300 mg BID and dasatinib 100 mg
OD has been approved and registered as first-line therapy in
several countries and is also included in the ELN and NCCN
recommendations, whereas the other options still remain in-
vestigational [5••].
More recently, it has been suggested that evaluation of the
so-called halving time at 90 days of therapy (i.e., at least a
halving of the BCR-ABL percentage at 3 months with respect
to that observed at diagnosis) may represent a useful way to
discriminate among imatinib-treated patients those patients
who are at real risk of failure to the imatinib therapy
and should therefore change TKI therapy, from those
who are simply late responders and can therefore remain
on the same therapy [35]. Similar data have been reported
by RQ PCR analysis using as control gene GUS instead
of ABL, in order to have a more exact evaluation of the
real amount of the disease burden present at diagnosis
[36]. In this case, however, the best discriminating cutoff
at 3 months is to reach a value of approximately one third
with respect to that present at diagnosis.
It is relevant however that, independently from the risk of
progression and of death, those that at 3 months show values
of BCR-ABL above 10 % have very scanty possibility to
achieve later on within a reasonable lapse of time a deep
molecular response (MR4 and MR4.5) that are conditions nec-
essary to have chances to remain in TFR after TKI therapy
discontinuation. This is true also for those patients who have a
good halving time but that remain above 10 % after 3 months
of therapy [35]. Indeed, to obtain a high rate of deepmolecular
responses, BCR-ABLIS should be already ≤1 % at 3 months,
as also those patients who at 3 months are between 10 and 1%
of BCR-ABLIS have lower possibilities of achieving MR4 or
MR4.5 in a reasonable period of time [21, 22].
In summary, present CML treatment guidelines include
EMR at 3 months as the first landmark for evaluating re-
sponses to TKI therapy, as BCR-ABLIS levels at this time
are key predictors of long-term outcomes for CML patients
not only in terms of PFS and of OS but also in terms of the
possibility of achieving later on the deep molecular responses
that have been associated with additional long-term benefits,
including the possibility of the suspension of the TKI therapy.
Certainly, the 3 months BCR-ABLIS level thresholds associ-
ated not only with an improved PFS and OS but also with an
increased possibility of achieving MR4 and MR4.5 are more
frequently obtainable with the use of second-generation TKIs
with respect to imatinib and we still do not know whether a
change in therapy at this time can really improve the final
outcomes of the patients. This, on the contrary to the NCCN
guidelines, is the main reason for sustaining the ELN recom-
mendation of a delayed decision to change therapy in absence
of an overt failure. However, a flexible position is probably
advisable. The change of TKI therapy should be decided in the
individual cases considering the goal expected to be achieved,
the probability of achieving that goal in a given patient, and
the final balance between the possible advantages and disad-
vantages, including the risk of toxicity and the economic cost,
that the achievement of the goal may require.
Detection of BCR-ABL Kinase Domain Mutations
The presence of BCR-ABL1 kinase domain point mutations is
suggestive of genetic instability and of increased risk of pro-
gression and is detectable in about 50 % of patients with treat-
ment failure and progression [17]. More than 80 amino acid
substitutions have been reported in association with resistance
to imatinib. Nilotinib-resistant patients were most frequently
found to have acquired Y253H, E255K/V, F359V/C/T315I
mutations, whereas dasatinib-resistant patients were found to
have acquired V299L, F317L/V/I/C, T315A, and T315I mu-
tations. The spectrum of mutations conferring resistance to
bosutinib is similar to that of dasatinib. Therefore, no
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second-generation TKIs are capable to inhibit the T315I mu-
tation that is only inhibited by ponatinib [37].
Mutational analysis should be performed in all cases of
treatment failure, of progression to accelerated phase or blast
crisis, in all the cases in which a consistent and confirmed
increase of the BCR-ABL transcript level is observed, and in
all cases in which a change of TKI therapy is performed [5••,
6••]. The mutation analysis in case of warning is not recom-
mended at the moment, as no data are available to provide
evidence that the analysis may be clinically significant in this
situation, but of course, it can be performed in specific cases
according to the clinicians’ discretion.
Finally, to date, the presence of mutated clones should be
assessed using low-sensitivity techniques (Sanger sequenc-
ing) [38]. In our days, the presence of very small subclones
with mutations can be identified with more sensitive tech-
niques, such as mass spectrometry or ultra-deep sequencing,
but data are not yet sufficient to interpret the clinical relevance
of the mutations detected by these more sensitive techniques.
Considerations and Conclusions
CML treatment is undergoing a profound evolution during the
last years. This is due to the fact that, besides imatinib, more
TKIs of second and of third generation with different efficacy
and toxicity profiles are now available and that the final end-
point of the therapy in a rather consistent percentage of pa-
tients can be represented not only by the best possible overall
survival with respect to a control population without leukemia
but also by achieving this goal without the need to assume
TKIs for the rest of the life. Because of this, not only the
choice of first-line treatment of CML in chronic phase but also
the way to harmonize the sequential use of the different TKIs
at disposition are at the moment the most hot topics of debate
among hematologists dealing with CML around the world.
The present recommendations indeed are bound to high-
light and to recommend only elements that have been suffi-
ciently proven in the literature, but of course, they cannot
cover all the different situations that are faced by clinicians
in real life. That is why a careful observation of the profile of
the individual patient in order to decide the therapy and its
possible modifications during follow-up is becoming the most
important and stringent recommendation. Of course, decisions
should be taken also on the basis of a precise evaluation of the
disease status and burden, both at diagnosis as well as in
response to treatment. On this purpose, precise and standard-
ized methods are needed and at the moment RQ PCR analysis,
even more than cytogenetic analysis, is becoming the method
of choice. As a fast initial response may be highly predictive
of the patients’ final outcome, a more intense schedule for
monitoring the response with cytogenetic and/or molecular
analysis within the first semester of therapy is advisable even
in common clinical practice, as clearly stated in the ELN and
NCCN recommendations [5••, 6••]. The RQ PCR technique is
also the only one able to evaluate the achievement of the very
low levels of residual disease which are needed to open the
possibility of achieving a TFR status [13]. In parallel with the
development of new and more potent TKIs and/or of suitable
combination therapies that could allow a higher percentage of
patients to achieve a TFR status, also a simplification and an
automation of standardized methods to assess the residual
disease are needed to expand the success of the CML therapy
on patients all over the world.
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